{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:29:06Z","timestamp":1790908146528,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.blre.2005.01.001","type":"journal-article","created":{"date-parts":[[2005,2,2]],"date-time":"2005-02-02T13:46:55Z","timestamp":1107352015000},"page":"243-252","source":"Crossref","is-referenced-by-count":48,"title":["Risk-adapted therapy in essential thrombocythemia and polycythemia vera"],"prefix":"10.1016","volume":"19","author":[{"given":"Guido","family":"Finazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2005.01.001_bib1","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Morbidity and mortality of a multicountry prospective cohort of 1638 patients with polycythemia vera. J Clin Oncol (in press)"},{"key":"10.1016\/j.blre.2005.01.001_bib2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia Vera: the natural history of 1213 patients followed over 20 years","volume":"123","author":"Gruppo Italiano Policitemia Vera (GISP)","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2005.01.001_bib3","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2005.01.001_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4065\/76.1.22","article-title":"A long-term retrospective study of young women with essential thrombocythemia","volume":"76","author":"Tefferi","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2005.01.001_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.001_bib6","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2005.01.001_bib7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1046\/j.1365-2141.1999.1331b.x","article-title":"Low-risk thrombocythemia in patients younger than 40","volume":"104","author":"Randi","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2005.01.001_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","article-title":"Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients","volume":"13","author":"Besses","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2005.01.001_bib9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V93.2.417","article-title":"A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications","volume":"93","author":"Harrison","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.001_bib10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0301-472X(01)00640-3","article-title":"Clonal hemopoiesis and risk of thrombosis in young females with essential thrombocythemia","volume":"29","author":"Chiusolo","year":"2001","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2005.01.001_bib11","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V100.2.714","article-title":"The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia","volume":"100","author":"Teofili","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.001_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2141.2003.04634.x","article-title":"Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythemia","volume":"123","author":"Johansson","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2005.01.001_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.10153","article-title":"Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia","volume":"71","author":"Ruggeri","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2005.01.001_bib14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1055\/s-0037-1613087","article-title":"Patients with essential thrombocytaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis","volume":"87","author":"Harrison","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2005.01.001_bib15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s002770000244","article-title":"The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia","volume":"80","author":"Jantunen","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2005.01.001_bib16","first-page":"73","article-title":"Erythromelalgic, thrombotic and hemorrhagic manifestations of thrombocythaemia","volume":"23","author":"van Genderen","year":"1994","journal-title":"Presse Med"},{"key":"10.1016\/j.blre.2005.01.001_bib17","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1046\/j.1365-2141.1996.d01-1729.x","article-title":"The reduction of large vonWillebrand multimers in plasma in essential thrombocythemia is related to the platelet count","volume":"93","author":"van Genderen","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2005.01.001_bib18","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.001_bib19","first-page":"6","article-title":"The very long term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981","volume":"34","author":"Najean","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2005.01.001_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2005.01.001_bib21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.1998.01021.x","article-title":"No treatment for low-risk essential thrombocythemia: results from a prospective study","volume":"103","author":"Ruggeri","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2005.01.001_bib22","first-page":"17","article-title":"From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2005.01.001_bib23","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.001_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/bjc.1981.150","article-title":"Treatment of polycythemia vera by radiophosphorus or busulphan. A randomizesd clinical trial","volume":"44","author":"Haanen","year":"1981","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2005.01.001_bib25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.7326\/0003-4819-119-11-199312010-00006","article-title":"Interferon alpha2b: a new treatment for polycythemia vera","volume":"119","author":"Silver","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2005.01.001_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002770050563","article-title":"Interferon alpha in the treatment of polycythemia vera","volume":"79","author":"Lengfelder","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2005.01.001_bib27","unstructured":"Silver RT, Fruchtman SM, Feldman EJ, Spivak JL, Salvado AJ. Imatinib mesylate (Gleevec) is effective in the treatment of polycythemia vera: a multi-institutional clinical trial. In: Abstract presented at the 46th American Society of Hematology Meeting, San Diego CA, 2004"},{"key":"10.1016\/j.blre.2005.01.001_bib28","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2005.01.001_bib29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodyslastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.001_bib30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6","article-title":"Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis","volume":"52","author":"Nand","year":"1996","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2005.01.001_bib31","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2003-01-0135","article-title":"Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis","volume":"101","author":"Finazzi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.001_bib32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2005.01.001_bib33","first-page":"177","article-title":"Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group","volume":"23","author":"Murphy","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2005.01.001_bib34","first-page":"70a","article-title":"Anagrelide: analysis of long term safety and leukemogenic potential in myeloproliferative diseases","volume":"100","author":"Fruchtman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.001_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia","volume":"97","author":"Storen","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.001_bib36","doi-asserted-by":"crossref","unstructured":"Green A, Campbell P, Buck G, et al. The Medical Research Council PT1 trial in essential thrombocythemia. In: Abstract Presented at the 46th American Society of Hematology Meeting, San Diego CA, 2004","DOI":"10.1182\/blood.V104.11.6.6"},{"issue":"suppl.1","key":"10.1016\/j.blre.2005.01.001_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/10428199609074371","article-title":"Interferon-alpha in the treatment of essential thrombocythemia","volume":"22","author":"Lengfelder","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2005.01.001_bib38","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/sj.leu.2402638","article-title":"Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosomal abnormalities in patients treated with pipobroman or hydroxyurea","volume":"16","author":"Bernasconi","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2005.01.001_bib39","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.V92.4.1465","article-title":"Multiple factors in the transformation of essential thrombocythemia to acute leukemia or myelodysplastic syndromes","volume":"92","author":"Liu","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.001_bib40","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V95.11.3589","article-title":"Acquired DNA mutations associated with in vivo hydroxyurea exposure","volume":"95","author":"Hanft","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.001_bib41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000204260","article-title":"Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation \u2013 a brief review of recent literature","volume":"91","author":"Shibata","year":"1994","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2005.01.001_bib42","doi-asserted-by":"crossref","unstructured":"Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera. An analysis of 1638 patients enrolled in a prospective observational study. Blood 2004;Dec 7:[Epub ahead of print]","DOI":"10.1182\/blood-2004-09-3426"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X05000020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X05000020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T15:16:10Z","timestamp":1586099770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X05000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0268960X05000020"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2005.01.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}